MARKET

RDY

RDY

Dr Reddys Labs
NYSE
69.53
-0.08
-0.11%
After Hours: 69.53 +0.01 +0.01% 16:00 05/24 EDT
OPEN
69.60
PREV CLOSE
69.61
HIGH
69.85
LOW
69.11
VOLUME
257.35K
TURNOVER
0
52 WEEK HIGH
77.72
52 WEEK LOW
53.12
MARKET CAP
11.58B
P/E (TTM)
17.35
1D
5D
1M
3M
1Y
5Y
PRESS DIGEST-British Business - May 27
Private equity executives have received a tax break worth as much as 4 billion pounds. State subsidies for offshore wind projects may be generous enough to drive clean energy projects. Eight people taken to hospital after a bout of heavy turbulence on a Qatar Airways flight. The top stories on the British business pages.
Reuters · 22h ago
Dr. Reddy’s Forays into Russian Diabetes Market
TipRanks · 3d ago
Dr. Reddy’s Invests Heavily in Subsidiaries
TipRanks · 3d ago
MEDIA-Indian pharma companies show interest in buying JB Chemicals from KKR - ET
Reuters · 3d ago
BUZZ-Alvotech rises on higher Q1 revenue
Shares of biotech company Alvotech SA rise to $ after the bell. Company reports higher Q1 revenue. Co says it has entered into an agreement with Dr. Reddy's to commercialize a biosimilar to Amgen's bone disease drug Prolia and Xgeva.
Reuters · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-ProShares Ether, International Business Machines, Alvotech
The main indexes oscillated within a tight range on Tuesday. Investors grew cautious ahead of AI chip leader Nvidia's earnings this week. Federal Reserve officials emphasized the central bank was in hurry to ease interest rates. At 13:44 ET, the Dow Jones Industrial Average and the S&P 500 were up.
Reuters · 6d ago
BUZZ-Alvotech rises on deal with Dr Reddy's on biosimilar to Amgen's bone drugs
Alvotech rises on deal with Dr Reddy's on biosimilar to Amgen's bone drugs. Co says it has entered into an agreement to commercialize a drug. Alvotech's shares rise to $7.50. The drug will be a biosimilar to Amogen's bone disease drugs Prolia and Xgeva.
Reuters · 6d ago
ALVOTECH SHARES UP 2.1% AS CO ENTERS INTO AGREEMENT WITH DR REDDY'S TO COMMERCIALIZE BIOSIMILAR TO AMGEN'S BONE DISEASE DRUGS PROLIA AND XGEVA
Reuters · 6d ago
More
About RDY
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Webull offers Dr Reddy's Laboratories Ltd (ADR) stock information, including NYSE: RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.